• Je něco špatně v tomto záznamu ?

Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia

J. Heilmann, S. Vieth, A. Möricke, A. Attarbaschi, D. Barbaric, N. Bodmer, A. Colombini, L. Dalla-Pozza, S. Elitzur, S. Izraeli, G. Mann, F. Niggli, D. Silvestri, J. Stary, C. Rizzari, MG. Valsecchi, E. Zapotocka, M. Zimmermann, G. Cario, M....

. 2023 ; 108 (12) : 3278-3286. [pub] 20231201

Jazyk angličtina Země Itálie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24000560

Although initial central nervous system (CNS) involvement is rarely detected in childhood acute lymphoblastic leukemia (ALL), risk-adapted CNS-directed therapy is essential for all patients. Treatment intensity depends on the initial CNS status. In the AIEOP-BFM ALL 2009 trial, patients with cytomorphologic detection of leukemic blasts in initial cerebrospinal fluid were classified as CNS2 or CNS3 and received five intrathecal doses of methotrexate (MTX) in induction therapy compared to patients with CNS1 status (no blasts detected) who received three doses. The impact of additional intrathecal (IT) MTX on systemic toxicity in induction therapy is unknown. Between June 1st 2010 and February 28th 2017, a total of 6,136 ALL patients aged 1-17 years were enrolled onto the AIEOP-BFM ALL 2009 trial. The effect of three versus five doses of IT MTX during induction therapy on the incidence of severe infectious complications was analyzed. Among 4,706 patients treated with three IT MTX doses, 77 (1.6%) had a life-threatening infection during induction as compared to 59 of 1,350 (4.4%) patients treated with five doses (P<0.001; Odds Ratio 2.86 [95% Confidence Interval 1.99-4.13]). In a multivariate regression model, treatment with additional IT MTX proved to be the strongest risk factor for life-threatening infections (Odds Ratio 2.85 [1.96-4.14]). Fatal infections occurred in 16 (0.3%) and 38 (1.6%) patients treated with three or five IT MTX doses, respectively (P<0.001). As the relevance of additional intrathecal MTX in induction for relapse prevention in CNS2 patients is unclear, doses of intrathecal therapy have been reduced for these patients. (Clinicaltrials.gov identifiers: NCT01117441 and NCT00613457).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24000560
003      
CZ-PrNML
005      
20240213093247.0
007      
ta
008      
240109s2023 it f 000 0|eng||
009      
AR
024    7_
$a 10.3324/haematol.2022.281788 $2 doi
035    __
$a (PubMed)37021527
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a it
100    1_
$a Heilmann, Janina $u Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany
245    10
$a Effect of two additional doses of intrathecal methotrexate during induction therapy on serious infectious toxicity in pediatric patients with acute lymphoblastic leukemia / $c J. Heilmann, S. Vieth, A. Möricke, A. Attarbaschi, D. Barbaric, N. Bodmer, A. Colombini, L. Dalla-Pozza, S. Elitzur, S. Izraeli, G. Mann, F. Niggli, D. Silvestri, J. Stary, C. Rizzari, MG. Valsecchi, E. Zapotocka, M. Zimmermann, G. Cario, M. Schrappe, V. Conter
520    9_
$a Although initial central nervous system (CNS) involvement is rarely detected in childhood acute lymphoblastic leukemia (ALL), risk-adapted CNS-directed therapy is essential for all patients. Treatment intensity depends on the initial CNS status. In the AIEOP-BFM ALL 2009 trial, patients with cytomorphologic detection of leukemic blasts in initial cerebrospinal fluid were classified as CNS2 or CNS3 and received five intrathecal doses of methotrexate (MTX) in induction therapy compared to patients with CNS1 status (no blasts detected) who received three doses. The impact of additional intrathecal (IT) MTX on systemic toxicity in induction therapy is unknown. Between June 1st 2010 and February 28th 2017, a total of 6,136 ALL patients aged 1-17 years were enrolled onto the AIEOP-BFM ALL 2009 trial. The effect of three versus five doses of IT MTX during induction therapy on the incidence of severe infectious complications was analyzed. Among 4,706 patients treated with three IT MTX doses, 77 (1.6%) had a life-threatening infection during induction as compared to 59 of 1,350 (4.4%) patients treated with five doses (P<0.001; Odds Ratio 2.86 [95% Confidence Interval 1.99-4.13]). In a multivariate regression model, treatment with additional IT MTX proved to be the strongest risk factor for life-threatening infections (Odds Ratio 2.85 [1.96-4.14]). Fatal infections occurred in 16 (0.3%) and 38 (1.6%) patients treated with three or five IT MTX doses, respectively (P<0.001). As the relevance of additional intrathecal MTX in induction for relapse prevention in CNS2 patients is unclear, doses of intrathecal therapy have been reduced for these patients. (Clinicaltrials.gov identifiers: NCT01117441 and NCT00613457).
650    _2
$a dítě $7 D002648
650    _2
$a lidé $7 D006801
650    12
$a methotrexát $x terapeutické užití $7 D008727
650    _2
$a indukční chemoterapie $x škodlivé účinky $7 D060828
650    12
$a akutní lymfatická leukemie $x komplikace $x farmakoterapie $7 D054198
650    _2
$a kombinovaná terapie $7 D003131
650    _2
$a protokoly antitumorózní kombinované chemoterapie $x škodlivé účinky $7 D000971
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vieth, Simon $u Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany. simon.vieth@uksh.de
700    1_
$a Möricke, Anja $u Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany
700    1_
$a Attarbaschi, Andishe $u Department of Pediatrics, St. Anna Children's Cancer Research Institute and St. Anna Children's Hospital, Medical University School, Vienna
700    1_
$a Barbaric, Draga $u Children's Cancer Institute Australia, University of New South Wales, Lowy Cancer Centre, Randwick, Australia; Kids Cancer Centre, Sydney Children's Hospital, Randwick, Australia
700    1_
$a Bodmer, Nicole $u Department of Pediatric Oncology, University Children's Hospital, Zuerich, Switzerland
700    1_
$a Colombini, Antonella $u Pediatric Clinic, University Milano-Bicocca-Fondazione MBBM/ San Gerardo Hospital, Monza, Italy
700    1_
$a Dalla-Pozza, Luciano $u The Children's Hospital at Westmead, Department of Oncology, Westmead, Australia
700    1_
$a Elitzur, Sarah $u Pediatric Hematology-Oncology, Schneider Children's Medical Center and Sackler Faculty of Medicine, Aviv University, Aviv, Israel
700    1_
$a Izraeli, Shai $u Pediatric Hematology-Oncology, Schneider Children's Medical Center and Sackler Faculty of Medicine, Aviv University, Aviv, Israel
700    1_
$a Mann, Georg $u Department of Pediatrics, St. Anna Children's Cancer Research Institute and St. Anna Children's Hospital, Medical University School, Vienna
700    1_
$a Niggli, Felix $u Department of Pediatric Oncology, University Children's Hospital, Zuerich, Switzerland
700    1_
$a Silvestri, Daniela $u Pediatric Clinic, University Milano-Bicocca-Fondazione MBBM/ San Gerardo Hospital, Monza, Italy; University of Milano-Bicocca, Center of Biostatistics for Clinical Epidemiology, Department of Health Science, Milan, Italy
700    1_
$a Stary, Jan $u University Hospital Motol, Department of Pediatric Hematology/Oncology, Prague, Czech Republic
700    1_
$a Rizzari, Carmelo $u Pediatric Clinic, University Milano-Bicocca-Fondazione MBBM/ San Gerardo Hospital, Monza, Italy
700    1_
$a Valsecchi, Maria Grazia $u University of Milano-Bicocca, Center of Biostatistics for Clinical Epidemiology, Department of Health Science, Milan, Italy
700    1_
$a Zapotocka, Ester $u University Hospital Motol, Department of Pediatric Hematology/Oncology, Prague, Czech Republic
700    1_
$a Zimmermann, Martin $u Hannover Medical School, Pediatric Hematology and Oncology, Hannover, Germany
700    1_
$a Cario, Gunnar $u Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany
700    1_
$a Schrappe, Martin $u Department of Pediatrics, Christian-Albrechts-University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany
700    1_
$a Conter, Valentino $u Pediatric Clinic, University Milano-Bicocca-Fondazione MBBM/ San Gerardo Hospital, Monza, Italy
773    0_
$w MED00001963 $t Haematologica $x 1592-8721 $g Roč. 108, č. 12 (2023), s. 3278-3286
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37021527 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240109 $b ABA008
991    __
$a 20240213093244 $b ABA008
999    __
$a ok $b bmc $g 2049304 $s 1210254
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 108 $c 12 $d 3278-3286 $e 20231201 $i 1592-8721 $m Haematologica $n Haematologica $x MED00001963
LZP    __
$a Pubmed-20240109

Najít záznam

Citační ukazatele

Možnosti archivace